e-learning
resources
Barcelona 2010
Tuesday, 21.09.2010
Pathogenesis of diffuse parenchymal lung disease
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Enhanced apoptosis of alveolar lymphocytes (AL), but not macrophages (AM) in interstitial idiopathic pneumonias (IIPs). Special attention to idiopathic pulmonary fibrosis (IPF) results
P. Kopinski, K. Szablowska, G. Przybylski, A. Jarzemska, G. Pinis, B. Balicka-Slusarczyk, A. Szlubowski, J. Szczeklik (Bydgoszcz, Krakow, Poland)
Source:
Annual Congress 2010 - Pathogenesis of diffuse parenchymal lung disease
Session:
Pathogenesis of diffuse parenchymal lung disease
Session type:
Thematic Poster Session
Number:
4179
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Kopinski, K. Szablowska, G. Przybylski, A. Jarzemska, G. Pinis, B. Balicka-Slusarczyk, A. Szlubowski, J. Szczeklik (Bydgoszcz, Krakow, Poland). Enhanced apoptosis of alveolar lymphocytes (AL), but not macrophages (AM) in interstitial idiopathic pneumonias (IIPs). Special attention to idiopathic pulmonary fibrosis (IPF) results. Eur Respir J 2010; 36: Suppl. 54, 4179
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Management of severe community acquired pneumonia – ERS guidelines
Panel discussion on genetics in pulmonary fibrosis
Related content which might interest you:
Alveolar lymphocytes (AL) apoptosis in interstitial lung diseases (ILD). Increased AL apoptosis rate in idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2009 - Pathogenesis of pulmonary fibrosis
Year: 2009
Elevated apoptosis rate of alveolar lymphocytes (AL) in idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonitis (NSIP) – strong positive correlation with bronchoalvoelar lavage (BAL) neutrophil count.
Source: Virtual Congress 2020 – Translational aspects of idiopathic pulmonary fibrosis
Year: 2020
Cykine/receptor inflammatory profile in different types of idiopathic intestitial pneumonias (IIPs). Key role of Fas Ligand recruvation in idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease
Year: 2010
Increased apoptosis of alveolar lymphocytes (AL) in idiopathic pulmonary fibrosis (IPF). Potential mechanisms and practical considerations
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013
Inhibition of local fibrinolysis differs between idiopathic pulmonary fibrosis (IPF) and fibrotic non-specific interstitial pneumonia (f-NSIP)
Source: Annual Congress 2009 - Idiopathic pulmonary fibrosis: concepts and mechanisms
Year: 2009
Clinical and functional features in idiopathic pulmonary fibrosis (IPF) with and without haemosiderin-laden alveolar macrophages on BALF
Source: Annual Congress 2011 - Bronchoalveolar lavage and biomarkers in diffuse parenchymal lung disease
Year: 2011
Comparative proteome analysis of lung tissue from patients with idiopathic pulmonary fibrosis (IPF) and non-specific interstitial pneumonia (NSIP)
Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease
Year: 2013
Cytokines, chemokines and growth factors concentration in BAL fluid from patients with Idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP)
Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis
Year: 2020
Idiopathic pulmonary fibrosis (IPF) and idiopathic nonspecific interstitial pneumonia (NSIP): what treatment and for whom?
Source: Annual Congress 2006 - Usual interstitial pneumonia (UIP) and nonspecific interstitial pneumonia (NSIP), idiopathic or not: new concepts in diagnosis and treatment
Year: 2006
Aerosolized interferon-gamma (IFN-γ) in idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2007 - Considerations in the therapeutic approach of interstitial lung disease: oxidative stress and inflammation
Year: 2007
Contribute of BAL proteomic analysis in sarcoidosis (S) and in idiopathic pulmonary fibrosis (IPF/UIP)
Source: Eur Respir J 2006; 28: Suppl. 50, 564s
Year: 2006
Serum surfactant protein D (SP-D) and annual decline of diffusion capacity are prognostic factors for combined pulmonary fibrosis with emphysema (CPFE) in idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2013 –Clinical respiratory physiology in different diseases
Year: 2013
Histology and pathogenesis of usual interstitial pneumonia (UIP)
versus
nonspecific interstitial pneumonia (NSIP): progressive remodeling or resolution and healing?
Source: Annual Congress 2006 - Usual interstitial pneumonia (UIP) and nonspecific interstitial pneumonia (NSIP), idiopathic or not: new concepts in diagnosis and treatment
Year: 2006
Non-IPF idiopathic interstitial pneumonia (IIPs)
Source: ERS Course 2016
Year: 2016
Difference in immunological aspects of inflammation in idiopathic pulmonary fibrosis (IPF) and exogenous toxic alveolitis (ETA)
Source: Eur Respir J 2003; 22: Suppl. 45, 121s
Year: 2003
Lysozyme level and activity are decreased in the lungs of patients with idiopathic pulmonary fibrosis (IPF) and potentially contribute to increased susceptibility to pulmonary infection
Source: Annual Congress 2006 - Usefulness of broncoalveolar lavage (BAL) in interstitial lung diseases
Year: 2006
Small airways structural alterations in usual interstitial pneumonia (UIP), non-specific interstitial pneumonia (NSIP), hypersensitivity pneumonia (HP) and chronic bronchiolitis (CB)
Source: Eur Respir J 2006; 28: Suppl. 50, 308s
Year: 2006
Treatment of idiopathic pulmonary fibrosis (IPF) with pentoxifylline (POF)
Source: Eur Respir J 2007; 30: Suppl. 51, 121s
Year: 2007
Idiopathic pulmonary fibrosis - IPF
Source: Respipedia Article
Year: 2018
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept